Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- non-conventional therapies »
- Cannabis-based Therapy in Myeloma
Cannabis-based Therapy in Myeloma
Cannabis-based therapy in myeloma should be considered for several medical challenges faced by MM patients that are currently not well addressed with FDA approved therapies.
And these medical challenges are:
- pain as both a symptoms and side effect-
- mind-body challenges-
- bone health-
Interestingly, the short video linked below discusses the same issues that the research linked below does. I found this video to be brief but clearly stating the benefits of CBD.
CBD for multiple myeloma: Benefits, risks & what science says!
As a long-term MM survivor, I live with a host of long-term side effects from the conventional therapies I underwent in ’94,’95 and ’96. I understand pain, anxiety and bone health personally.
While I am the first person to state that cannabis-based therapy in myeloma is not a silver bullet, I am here to tell you that CBD oil has a place in my daily non-conventional therapies.
Two droppers under my tongue before bed every night to be specific. I take a brand called Charlotte’s Web. No THC.
Email me at David.PeopleBeatingCancer@gmail.com to learn more about managing your MM as well as your therapy-induced side effects.
Good luck,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Cannabinoids in the management of difficult to treat pain
“This article reviews recent research on cannabinoid analgesia via the endocannabinoid system and non-receptor mechanisms, as well as randomized clinical trials employing cannabinoids in pain treatment.
Tetrahydrocannabinol (THC, Marinol®) and nabilone (Cesamet®) are currently approved in the United States and other countries, but not for pain indications. Other synthetic cannabinoids, such as ajulemic acid, are in development. Crude herbal cannabis remains illegal in most jurisdictions but is also under investigation.
Sativex®, a cannabis derived oromucosal spray containing equal proportions of THC (partial CB1 receptor agonist ) and cannabidiol (CBD, a non-euphoriant, anti-inflammatory analgesic with CB1receptor antagonist and endocannabinoid modulating effects) was approved in Canada in 2005 for treatment of central neuropathic pain in multiple sclerosis, and in 2007 for intractable cancer pain.
Numerous randomized clinical trials have demonstrated safety and efficacy for Sativex in central and peripheral neuropathic pain, rheumatoid arthritis and cancer pain. An Investigational New Drug application to conduct advanced clinical trials for cancer pain was approved by the US FDA in January 2006.
Cannabinoid analgesics have generally been well tolerated in clinical trials with acceptable adverse event profiles. Their adjunctive addition to the pharmacological armamentarium for treatment of pain shows great promise…”
Cannabidiol as a Potential Treatment for Anxiety Disorders
“Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders.
The purpose of the current review is to determine CBD’s potential as a treatment for anxiety-related disorders, by assessing evidence from preclinical, human experimental, clinical, and epidemiological studies.
We found that existing preclinical evidence strongly supports CBD as a treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, obsessive–compulsive disorder, and post-traumatic stress disorder when administered acutely; however, few studies have investigated chronic CBD dosing.
Likewise, evidence from human studies supports an anxiolytic role of CBD, but is currently limited to acute dosing, also with few studies in clinical populations. Overall, current evidence indicates CBD has considerable potential as a treatment for multiple anxiety disorders, with need for further study of chronic and therapeutic effects in relevant clinical populations…”
“A new study published in the Journal of Bone and Mineral Research by Tel Aviv University and Hebrew University researchers explores another promising new medical application for marijuana.
According to the research, the administration of the non-psychotropic component cannabinoid cannabidiol (CBD) significantly helps heal bone fractures. The study, conducted on rats with mid-femoral fractures, found that CBD — even when isolated from tetrahydrocannabinol (THC), the major psychoactive component of cannabis — markedly enhanced the healing process of the femora after just eight weeks.
The research was led jointly by Dr. Yankel Gabet of the Bone Research Laboratory at the Department of Anatomy and Anthropology at TAU’s Sackler Faculty of Medicine and the late Prof. Itai Bab of Hebrew University’s Bone Laboratory…”
Cannabis-based therapy in myeloma Cannabis-based therapy in myeloma Cannabis-based therapy in myeloma